Ying Fan

Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Fei Ma, Qiao Li, Shanshan Chen et al. · Journal of Clinical Oncology · 2017 · 228 citations

Metastatic Breast Cancer, Oncology, Biomarker Analysis +12

Enriched CD44+/CD24− population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC)

Fei Ma, Huihui Li, Haijuan Wang et al. · Cancer Letters · 2014 · 148 citations

Tumor Biology, Enriched Cd44+/cd24− Population, Aggressive Phenotypes +13

The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the first‐line chemotherapy of HER2‐negative metastatic breast cancer

Xiuwen Guan, Fei Ma, Chunxiao Li et al. · Cancer Communications · 2019 · 113 citations · Full text

RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies.

Jiayu Wang, Yunjiang Liu, Qingyuan Zhang et al. · Journal of Clinical Oncology · 2021 · 102 citations

Breast Oncology, Immunology, Immunotherapeutics +18

Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial

Qiao Li, Xiuwen Guan, Shanshan Chen et al. · Clinical Cancer Research · 2019 · 89 citations